Record revenue masks earnings collapse and margin shortfall

Delivered ₹7,119.3 Cr; claim verified

Yurpeak ₹80 Cr = ~1.5% of growth; organic ex-new products ~7-8% per analyst calc

Q1 delivered 16.7% EBITDA (call disclosure), 180 bps below guidance floor

Delivered ₹785.5 Cr; negligible variance

Q1 $162M; needs $938M more in 9 months from binary approvals; Advair now $50-100M peak (not $100M+)

Verified per management; reported headline -5% due to tender decline + currency headwind

Prior: 18.5-20% for FY27. Q1 delivered 16.7%. Management maintains 18.5-20% is "broadly unchanged" but now contingent on new launches. Adds execution risk to guidance.

Prior: $1B by end FY27. Q1: $162M (2.3% of annual target with 75% of year remaining). Requires 6.2x growth via new approvals—binary and timing dependent.

Prior Q4 call: Potential FY27 revenue. Now: Two-pronged approach (FDA remediation + site transfer) with "timing fluid." Explicitly excluded from projections.

Reported 12% Q1 YoY. Analysts calculated ~7-8% ex-Yurpeak (₹80 Cr = 1.5% of total growth). Management didn't rebut; implies base organic momentum weaker than headline.

Prior: Private market outperformance. Q1: -5% reported, but 6.5% private market growth overshadowed by 23% currency tailwind loss + tender decline (expected to continue).

Overall reported 2%, adjusted ~4% YoY. Impact primarily South Africa. India 12% includes Yurpeak ₹80 Cr (~1.5%) and licensed products; balance from organic base at market-leading rates.

IQVIA data at 15.4% on Rx; ₹80 Cr from Yurpeak is 1.5%. Analyst's independent calc lands on 7-8%; management did not rebut, implying base is mid-single digits.

Tender business has declined; impact will continue through year. Private market growing 6.5% faster than market 5.7%, but currency hedges and accounting change mask it in headline.

Yes, unchanged. New products are large; base not big enough for delta. Visibility comes from successful approvals and Ventolin scale-up in coming quarters.

Broadly unchanged. Guidance predicated on launches and margin improvement (sequential path).

Not steady-state margin. Capex for launches committed (facilities, staffing) but products not yet approved; war costs (1-2%); product mix. Temporary transit phase; gradual improvement expected sequentially.

All very sizable opportunities. Assumes current competitive position unchanged. See large opportunity; don't expect competitive position to shift in 9 months.

Commenced commercial shipments at current scale. Work ongoing; full ramp expected towards end of financial year (Q4).

Our bet on tirzepatide (dual mode). High-involvement therapy; need prescriber guidance. Reached #2 after Mounjaro. Generic market crowded but different segment. Progressive growth expected as patient comfort builds.

Highly complex product; launch contingent on overcoming complexity, not litigation or patent variables. Can launch on FDA approval. Product off-patent. Awaiting approval; ready to launch upon clearance.

~12,000 field force. Not looking at significant manpower additions this year (added heavily last 2 years). Focus on productivity initiatives and reorganization within same headcount.

In line with market on acute; strong beat on respiratory (key chronic); chronic momentum strong. Acute tracking market.

Refrain from next-year guidance. Direction clear: current level below steady-state. 18.5-20% for FY27 reaffirmed. Expect improvements in coming quarters (sequential trajectory).

Q1 $162M; needs $938M in 9 months from 4 pending US FDA approvals (3 respiratory, 1 peptide). Ventolin ramp to Q4. Timing binary; competitive position assumed stable.

Q1 delivered 16.7% (180 bps below floor). Management maintains guidance is "broadly unchanged" but contingent on new product approvals coming through and sequential margin recovery. Capex drag expected to ease as facilities utilized.

R&D ₹486 Cr (6.8% of revenue) in Q1. Facilities staffed and batches ready for launches pending approvals; capex committed regardless of approval timing.

North America $1B guidance entirely contingent on FDA approvals for 3 respiratory assets and 1 peptide (unspecified). Q1 $162M vs implied $200-250M quarterly required. Any slip cascades to full-year miss.

Q1 16.7% EBITDA vs 18.5-20% FY27 guidance (180 bps shortfall). Management attributes to launch capex (facilities ready, no revenue), war costs (1-2%), product mix. No timeline given for recovery to guidance range.

PAT ₹786 Cr vs ₹1,288 Cr prior year Q1 (-39.2%). Revenue up only 2.3%. Gap suggests either structural cost inflation, margin compression, or one-off charges not fully disclosed. No management explanation in prepared remarks.

Reported 12% India growth but Yurpeak ₹80 Cr (~1.5% of total), licensed products, and accounting change adjustments removed imply ~7-8% organic base. Market-leading Rx (15.4%) is real, but analyst pushback suggests base momentum weaker than headline.

Reported -5% YoY (rupee terms). Private market growing 6.5% faster than market (5.7%) but overshadowed by tender decline (expected to persist) and 23% currency hedging impact. Structural shift away from tender business.

Ventolin has 6-month CGT exclusivity; Advair now has 3-4 competitors (down from premium opportunity). Peptide is said to be first-mover potential but complexity high. Market share assumptions may be optimistic if competition arrives faster than expected.

Explicitly excluded from FY27 projections. Two-pronged approach (Pharmathene remediation + US site tech transfer) running in parallel but timing "fluid" per management. No revenue expected in FY27.